All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 5:1 split | DEC 2020 ~13.6:1 split |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $0 | – | – | – | – | – |
| Cost of Revenue | $0 | – | – | – | – | – |
| Gross Profit | $0 | – | – | – | – | – |
| Operating Expenses | ||||||
| Selling & Marketing | – | $0 | $0 | $0 | – | $0 |
| General & Administrative | $1 | $2 | $2 | $1 | $1 | $0 |
| Research & Development | – | $1 | $1 | $1 | $1 | $0 |
| Total Operating Expenses | $1 | $3 | $2 | $2 | $2 | $1 |
| Operating Income | -$1 | -$3 | -$2 | -$2 | -$2 | -$1 |
| Non-Operating | ||||||
| Net Interest Expense | -$0 | – | – | – | -$0 | -$0 |
| Other Non-Operating Income (Expense) | -$3 | -$1 | -$2 | -$1 | -$1 | $0 |
| EBT (Earnings Before Tax) | -$4 | -$3 | -$4 | -$3 | -$3 | -$1 |
| Earnings from Continuing Ops | -$3 | – | – | – | – | – |
| Net Income | ||||||
| Net Income | -$1 | -$3 | -$4 | -$3 | -$3 | -$1 |
| Per Share Data | ||||||
| Revenue Per Share | $0.62 | – | – | – | – | – |
| EPS (Basic) | -$264.72 | -$2.51 | -$3.77 | -$3.13 | -$3.20 | -$6.85 |
| EPS (Diluted) | -$264.72 | -$2.51 | -$3.77 | -$3.13 | -$3.30 | -$6.85 |
| Weighted Avg Shares (Basic) | 638,789 | 1.3M | 1.1M | 37.4M | 36.4M | 7.4M |
| Weighted Avg Shares (Diluted) | 638,789 | 1.3M | 1.1M | 37.4M | 36.4M | 7.4M |
| Shares Outstanding | 15,969.725 | 1.3M | 1.1M | 934,914.775 | 909,914.625 | 183,781.8 |
Sigyn Therapeutics (SIGY) financials: revenue, profit and margins
Sigyn Therapeutics (SIGY) generated about n/a in revenue and -$3 million in net income over the trailing twelve months, growing at roughly 35.0% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Sigyn Therapeutics profitable?+
Sigyn Therapeutics reported about -$3 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
How fast is Sigyn Therapeutics growing?+
Sigyn Therapeutics's revenue has compounded at roughly 35.0% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside SIGY's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 14 Nov 2025, covering the period ending 30 Sept 2025, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Surgical & Medical Instruments & Apparatus · Pick stocks to compare with SIGY
Spot a number that looks wrong? Check it in SIGY's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SIGY
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.